• Recruiting

NCT04405167: Phase 1: Tasquinimod for the Treatment of Relapsed or Refractory Myeloma

NCT04405167: Phase 1: Tasquinimod for the Treatment of Relapsed or Refractory Myeloma

Tasquinimod

NCT04405167: Phase 1: Tasquinimod for the Treatment of Relapsed or Refractory Myeloma


This study is the first study of tasquinimod, an inhibitor of S100A9, in patients with multiple myeloma.


Sponsor

University of Pennsylvania


Collaborator

Active Biotech AB

 

ClinicalTrials.gov Identifier: NCT04405167

Official Title: Phase 1 Study of Tasquinimod Alone and in Combination With Standard Therapy for Relapsed or Refractory Myeloma

First Posted : May 28, 2020

Click here to see details on ClinicalTrials.gov

 

Drug: Tasquinimod

Drug: IRd chemotherapy with ixazomib, lenalidomide, and dexamethasone

 

Tasquinimod

Tasquinimod (Code C74080)

ABR-215050

TASQ

Tasquinimod

TASQUINIMOD

 

Location

United States, Pennsylvania



Posts Archive